,
“Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events.”, Hum Vaccin Immunother, vol. 8, no. 5, pp. 630-8, 2012.
, “Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.”, PLoS One, vol. 5, no. 9, p. e12873, 2010.
, “Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates.”, J Infect Dis, vol. 201, no. 5, pp. 720-9, 2010.
, “CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa.”, PLoS One, vol. 4, no. 2, p. e4401, 2009.
, “Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials.”, PLoS One, vol. 3, no. 4, p. e2043, 2008.
,